DEFA14A: LAVA Therapeutics Delays XOMA Acquisition Vote

LAVA Therapeutics N.V. has cancelled its Extraordinary General Meeting to approve the XOMA Royalty Corporation acquisition, rescheduling it for early November 2025 to finalize transaction terms.

Summary

• LAVA Therapeutics N.V. cancelled its Extraordinary General Meeting (EGM) originally scheduled for September 30, 2025.
• The EGM was intended to consider and approve matters related to the previously announced acquisition by XOMA Royalty Corporation.
• The cancellation is to allow for further discussions with XOMA regarding the transaction terms, specifically LAVA's estimated cash forecast and the consideration payable to shareholders.
• The EGM is now expected to be reconvened by early November 2025, with new dates and location to be announced later.
• Votes previously cast by shareholders will not be counted, requiring shareholders to re-cast their votes for the reconvened EGM.
• Both LAVA Therapeutics and XOMA Royalty Corporation remain committed to completing the acquisition.
• The acquisition is anticipated to close in the fourth quarter of 2025.

Sentiment

Score: 4

Explanation: The delay in the shareholder meeting and the need for further discussions on transaction terms, particularly cash forecasts and shareholder consideration, introduce uncertainty and a potential for less favorable outcomes. While both parties remain committed, the unresolved financial details are a negative development, though not a complete deal collapse.

Positives

• Both LAVA Therapeutics and XOMA Royalty Corporation explicitly state their commitment to completing the acquisition.
• The acquisition is still anticipated to close in the fourth quarter of 2025, indicating continued progress towards the transaction.

Negatives

• The Extraordinary General Meeting (EGM) for approving the XOMA acquisition was cancelled, introducing uncertainty and a delay.
• The cancellation is due to ongoing discussions regarding the transaction terms, specifically LAVA's estimated cash forecast and the consideration payable to shareholders, suggesting unresolved financial aspects.
• Shareholders who previously voted will need to re-cast their votes for the reconvened EGM, potentially causing inconvenience.
• The delay could lead to revised terms that are less favorable to LAVA's shareholders.

Risks

• The transaction with XOMA Royalty Corporation may not be completed in a timely manner, or at all, which could adversely affect LAVA's business and share price.
• The terms of the transaction may be revised to be less favorable to LAVA's shareholders.
• There is a risk of delay or failure for the revised terms to be agreed upon or for offer conditions to be satisfied (or waived), including insufficient common shares being tendered.
• Such delays could impact the amount payable to LAVA's shareholders in the transaction.
• The possibility exists that competing offers for LAVA Therapeutics may emerge.
• Significant costs are associated with the transaction.
• Any shareholder or other litigation related to the transaction could result in significant costs of defense, indemnification, and liability.
• Activities related to the Contingent Value Right (CVR) agreement may not result in any value to LAVA's shareholders.
• Prior to the completion of the transaction, LAVA's or XOMA's business may experience significant disruptions due to transaction-related uncertainty.
• The announcement and pendency of the transaction may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, or business partners.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the purchase agreement.
• Potential adverse effects on LAVA's business condition and results from general economic and market conditions and overall fluctuations in the United States and international equity markets, including inflation, heightened interest rates, recent and potential future pandemics, and hostilities (e.g., Russian invasion of Ukraine, Middle East conflict).

Future Outlook

The acquisition by XOMA Royalty Corporation is still anticipated to close in the fourth quarter of 2025, despite the delay in the shareholder meeting. The companies are working to finalize the cash forecast and consideration terms.

Management Comments

• "We are committed to closing this transaction and look forward to working collaboratively with the LAVA team to further define LAVAs cash forecast in an effort to close this transaction in an expeditious manner." Owen Hughes, CEO of XOMA Royalty.

Industry Context

This announcement reflects a common occurrence in M&A transactions, where complex financial details, such as cash forecasts and final consideration, require additional negotiation time. In the biopharmaceutical sector, such transactions often involve intricate valuations of pipelines and intellectual property, making precise cash flow projections critical for both parties. The commitment from both LAVA and XOMA to complete the transaction, despite the delay, suggests that the strategic rationale for the merger remains strong.

Stakeholder Impact

• Shareholders: Will experience a delay in the acquisition process and face uncertainty regarding the final terms and consideration. They will also need to re-cast their votes. There is a risk of less favorable terms.
• Employees, Manufacturers, Suppliers, Vendors, Business Partners: May experience significant disruptions due to transaction-related uncertainty, making it more difficult to establish or maintain relationships.

Next Steps

• LAVA Therapeutics will continue discussions with XOMA Royalty Corporation regarding the transaction terms, including the estimated cash forecast and shareholder consideration.
• LAVA Therapeutics will determine and announce the new meeting date, record date, and location for the reconvened Extraordinary General Meeting (EGM).
• Shareholders will need to re-cast their votes for the reconvened EGM.
• The acquisition is anticipated to close in the fourth quarter of 2025.

Key Dates

Recommendation

The cancellation of the EGM and the need for further discussions on the transaction's financial terms introduce a degree of uncertainty. While both parties remain committed to the acquisition, the potential for revised terms, which could be less favorable, warrants caution. A "hold" recommendation allows investors to await clarity on the finalized terms and the reconvened EGM without exiting a potentially still-beneficial transaction, while acknowledging the increased risk.

Keywords

LAVA Therapeutics, XOMA Royalty Corporation, Acquisition, Merger, EGM, Shareholder Meeting, Tender Offer, Biopharmaceutical, LVTX, Corporate Governance